As the Central Government is laying out a roadmap for Covid-19 vaccine distribution, more than 50 percent of India’s population has expressed caution towards taking the coronavirus vaccine, a survey revealed on Thursday.
The GOQii Covid-19 – The Way Forward survey was conducted with approximately 11,000 respondents to understand the openness to take the vaccine, the perception of the government measures to combat Covid-19, possible future measures including a lockdown.
About 53 percent of the population is unsure about taking the Covid-19 vaccine, the survey Revealed.
The survey further added that out of them, 43 percent revealed that they are not sure and will only make a solid opinion post initial results about the effectiveness of the vaccine is revealed while 10 percent are firmly against taking the vaccine as of now.
On an optimistic note, 47 percent of the respondents said that they are willing to take the vaccine and are actually waiting for it.
With age, the willingness to take the vaccine reduces. The older adults (45-60) and seniors (60+) are not as ready as the younger age groups. This may be due to concerns about complications post taking it.
It also revealed that 48 percent of the male population willing to get vaccinated while female readiness is around 42 percent.
According to the study, 50 percent of the respondents feel that the Central Government’s initiatives have been effective in curbing the spread of Covid-19 while 25 percent of people believe that the State Government initiatives have been effective. Only 22% of citizens recognize the efforts of the Local Government in terms of effectiveness.
Notably, 34 percent feel that a complete lockdown should be introduced again while 66 percent of the population surveyed believed the current method or opening up slowly is the way forward. Although 10 percent of people said that there should be no restrictions and things should go back to normal.
This survey holds importance at a time when questions are being raised on both the safety and efficacy of the vaccines and as many as eight Covid-19 vaccine candidates are under different stages of clinical trials which could be ready for authorization in near future, including three indigenous vaccines.
It includes Astrazeneca and Oxford university developed and Serum Institute of India manufactured Covishield, Covaxin by Bharat Biotech Limited, ZyCoV-D by Zydus Cadila, Russian vaccine candidate Sputnik-V, NVX-CoV2373 by SII, HGCO19 by Geneva, and two unlabelled vaccines-Recombinant Protein Antigen based vaccine by Biological E Limited-and Inactivated rabies vector platform by Bharat Biotech.
